UP!

ABCO $70   View long term graphs

The Advisory Board Company
Type
Public
Traded as NASDAQ: ABCO
Industry Health care and education, best practices, research, technology, consulting
Founded 1979
Founder David G. Bradley
Headquarters Washington, DC, United States
Area served
Worldwide
Key people
Robert Musslewhite (CEO, Chairman)
David Felsenthal
• President
Michael Kirshbaum
• Chief Financial Officer
Mary Van Hoose
• Chief Talent Officer
Chas Roades
• Chief Research Officer, Health Care Practice
Scott Fassbach
• Chief Research Officer, Education Practice
Number of employees
3,600
Website advisoryboardcompany.com

The Advisory Board Company is a best practices firm that uses a combination of research, technology, and consulting to improve the performance of health care organizations and educational institutions.

The company was founded by David G. Bradley in 1979 as the Research Council of Washington with five employees. Its original mission was to answer "any question for any company for any industry," but in 1983 the company began to specialize in research for the financial services industry and changed its name to The Advisory Board Company. By 1986, the company had launched its health care-focused strategic research division, including its first membership program, the Health Care Advisory Board.

Across the next four years the firm grew to 150 employees, served more than 500 health care members, and published 15 major reports and 2,000 research briefs each year. In 1993, the firm launched a strategic research membership for large companies, bringing on almost half of the Fortune 500 within 18 months. The firm expanded in 1994 to include its first clinically based program, the Cardiology Roundtable—which has since evolved to become the Cardiovascular Roundtable—providing best practices to the nations’ cardiac programs.

In 1997, the company spun off its corporate membership group, forming The Corporate Executive Board (now CEB Inc.) as an independent company. It maintained its focus on the health care sector, working with more than 1,500 health care organizations. H*Works, a consulting business offering best practice implementation support launched in 2000, followed shortly by The Advisory Board Company’s initial public offering in 2001, in which Bradley sold his ownership interest.

By 2002, the firm topped 2,100 memberships and 500 employees, and launched The Advisory Board Academies leadership development division—now the company's Talent Development division—to address the leadership gap in health care. In 2003, the company was named to Washingtonian’s Great Places to Work and launched its business intelligence and analytics offering, Compass, providing memberships anchored by robust decision support tools. In 2005, the firm was named to Forbes’ Top 200 High-Growth Companies and again to Washingtonian's Great Places to Work.

In 2007, the company launched its first membership programs in higher education, working with student and academic affairs executives at several U.S. research universities. The firm continued to grow across 2008, acquiring Crimson, a data, analytics, and business intelligence software provider focused on physician performance, quality metrics, and cost of care outcomes.

By 2009, The Advisory Board Company had opened its doors in San Francisco, marking the fourth U.S. office. The firm also grew to over 1,000 employees and over 2,800 health care and higher education members. The company expanded its capabilities in the physician management terrain through the acquisition of Southwind, a management and consulting firm focused on aligning hospitals and physicians through a comprehensive set of physician employment, clinical integration, and information technology deployment solutions. During this time,the company was named to Modern Healthcare’s Best Places to Work—an honor it has received every year since.

From 2010 to 2011, the company continued to expand, acquiring and partnering with a series of technology firms, including Milliman MedInsight, which provides population risk analytics, Cielo MedSolutions, which provides ambulatory patient registry software, and PivotHealth, a physician practice management firm.

In 2012, The Advisory Board Company acquired ActiveStrategy, a performance improvement technology firm, and 360Fresh, a leading provider of clinical data analytics. The firm also was named as one of Healthcare Informatics' top 100 health care IT firms and Modern Healthcare's top 40 fastest-growing health care firms list. During that year, the firm also provided $1 million in benefit to non-profit organizations through its Community Impact program.

In 2013, the firm was named the “#1 Best Large Company to Work For” by Modern Healthcare magazine. It also became the first for-profit company of its size to achieve 100% participation in community service.

That year, the Advisory Board acquired Care Team Connect, a care management workflow platform, and launched the Student Success Collaborative, a software-based program that helps colleges and universities improve outcomes for at-risk and off-path students. The company also announced the acquisition of Medical Referral Source, a technology firm with software that facilitates a seamless referral process.

2014 brought the acquisitions of HealthPost, which helps health systems reduce referral leakage and attract new patients, and Royall & Company, which provides the higher education industry with data-driven student engagement, enrollment management, financial aid optimization, and alumni fundraising solutions.

The company’s Community Impact program, meanwhile, received the 2014 Corporate Engagement Award of Excellence from Points of Light, the world's largest organization dedicated to volunteer service. The firm also partnered with the de Beaumont Foundation, Kresge Foundation, and Robert Wood Johnson Foundation to launch the BUILD Health Challenge to identify and support health partnerships taking bold, upstream, integrated, local, and data-driven approaches to improving health in low-income, urban communities.

In 2015, the company announced its acquisition of Clinovations, an EMR optimization firm serving providers at the intersection of clinician workflows and information technology, and GradesFirst, a student success technology company with workflow software that enables colleges and universities to identify, engage, and support at-risk students.

As of 2016, the company had grown to more than 3,600 employees, with offices on three continents. It was named as a Modern Healthcare Best Place to Work for the eighth straight year.

In January 2017, the company reduced it's healthcare workforce by 220 employees, or 5.7%, exited several businesses and announced a plan to close 4 offices by the end of 2017.

On August 29, 2017, the company announced the completion of their nine-month strategic review with a sale and split of its two business units. The health care business was acquired by Optum, a global health company, and the education business was acquired by Vista, a leading investment firm. The total value of the deal was roughly $2.5B and is expected to close in late 2017 or early 2018, after customary review proceedings conclude.

The company’s advisory board division serves 4,400+ health care members. Advisory Board forges and finds best practices, then customizes and hardwires those insights for members with research, technology, and consulting. It also publishes American Health Line, a daily health care policy briefing.

Advisory Board Research provides clarity on health care's pressing issues—including strategy, care delivery, and operations—and strategies for addressing them.

Advisory Board Technology services help members find and address opportunities by embedding best practices into operations.

The Advisory Board Consulting team provides hands-on best practice implementation, practice management solutions, and physician alignment services.

The company’s EAB division serves 1,100+ college and university members. EAB forges and finds best practices to address education’s top challenges with research forums dedicated to presidents, provosts, chief business officers, and other academic and administrative leaders.

News

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q1 2018 2018-05-07 Future report Set alerts
Q4 2017 2018-02-26 Future report Set alerts
Q3 2017 2017-11-08 0.27 0.00
Q2 2017 2017-08-08 0.37 0.36
Q1 2017 2017-05-04 0.47 0.48
Q4 2016 2017-02-28 1.03 0.88
Q3 2016 2016-11-01 0.28 0.93
Q2 2016 2016-07-27 0.47 0.18
Q1 2016 2016-05-05 0.46 0.25
Q4 2015 2016-02-23 0.48 -2.51

Ratings

2016-06-20 Initiated Coverage Credit Suisse Outperform $40.00
2016-06-20 Initiated Coverage Credit Suisse Group AG Outperform $40.00
2016-05-29 Reiterated Rating Canaccord Genuity Buy
2016-05-22 Reiterated Rating KeyBanc Hold
2016-05-22 Reiterated Rating KeyCorp Hold
2016-05-12 Boost Price Target SunTrust Buy $35.00 to $40.00
2016-05-12 Boost Price Target SunTrust Banks Inc. Buy $35.00 to $40.00
2016-05-08 Reiterated Rating FBR & Co. Hold
2016-05-08 Reiterated Rating Robert W. Baird Hold
2016-05-08 Reiterated Rating FBR & Co Hold
2016-05-06 Upgrade Avondale Partners Market Perform to Outperform
2016-05-06 Lower Price Target FBR & Co. Mkt Perform $40.00 to $35.00
2016-05-06 Reiterated Rating Canaccord Genuity Buy $50.00
2016-05-02 Boost Price Target Avondale Partners Market Perform $34.00
2016-02-26 Lower Price Target Raymond James Outperform $57.00 to $40.00
2016-02-26 Lower Price Target Piper Jaffray $66.00 to $39.00
2016-02-26 Lower Price Target JPMorgan Chase & Co. Overweight $64.00 to $57.00
2016-02-26 Lower Price Target Raymond James Financial Inc. Outperform $57.00 to $40.00
2016-02-26 Lower Price Target Piper Jaffray Cos. $66.00 to $39.00
2016-02-25 Upgrade Deutsche Bank Hold to Buy $53.00 to $43.00
2016-02-25 Upgrade Deutsche Bank AG Hold to Buy $53.00 to $43.00
2016-02-24 Lower Price Target Oppenheimer Outperform $65.00 to $40.00
2016-02-24 Downgrade Craig Hallum Buy to Hold $64.00 to $36.00
2016-02-24 Lower Price Target Canaccord Genuity Buy $63.00 to $50.00
2016-02-24 Downgrade Cantor Fitzgerald Buy to Hold $60.00 to $32.00
2016-02-24 Downgrade Stifel Nicolaus Buy to Hold
2016-02-24 Downgrade Robert W. Baird Outperform to Neutral $60.00 to $40.00
2016-02-24 Downgrade FBR & Co. Outperform to Market Perform $55.00 to $40.00
2016-02-24 Lower Price Target Barclays Overweight $63.00 to $41.00
2016-02-24 Lower Price Target Oppenheimer Holdings Inc. Outperform $65.00 to $40.00
2016-02-24 Lower Price Target Barclays PLC Overweight $63.00 to $41.00
2016-02-23 Downgrade Avondale Partners Outperform to Market Perform $51.00 to $31.00
2016-02-22 Lower Price Target Avondale Partners Market Outperform $65.00 to $51.00
2016-01-26 Reiterated Rating FBR & Co. Outperform $55.00
2015-11-17 Initiated Coverage JPMorgan Chase & Co. Overweight $64.00
2015-11-09 Initiated Coverage Cantor Fitzgerald Buy $60.00
2015-11-06 Lower Price Target Raymond James Outperform $64.00 to $57.00
2015-11-06 Reiterated Rating Canaccord Genuity Buy $65.00 to $63.00
2015-11-06 Reiterated Rating Piper Jaffray Buy $67.00 to $66.00
2015-10-12 Upgrade FBR & Co. Market Perform to Outperform $55.00
2015-09-29 Reiterated Rating William Blair Buy
2015-09-28 Reiterated Rating Canaccord Genuity Buy $65.00
2015-09-23 Reiterated Rating William Blair Outperform
2015-09-10 Reiterated Rating William Blair Buy
2015-08-31 Upgrade BMO Capital Markets Market Perform to Outperform
2015-08-17 Upgrade Robert W. Baird Neutral to Outperform $55.00 to $60.00
2015-08-05 Lower Price Target Barclays Overweight $65.00 to $63.00
2015-08-05 Reiterated Rating Canaccord Genuity Buy $66.00 to $65.00
2015-08-05 Reiterated Rating Oppenheimer Outperform $65.00 to $61.00
2015-07-28 Reiterated Rating Canaccord Genuity Buy
2015-07-16 Initiated Coverage Canaccord Genuity Buy $66.00 to $66.00
2015-07-15 Reiterated Rating Avondale Partners Buy $66.00
2015-07-15 Reiterated Rating Oppenheimer Outperform $65.00
2015-07-09 Reiterated Rating William Blair Outperform
2015-06-18 Initiated Coverage Stephens Outperform $65.00
2015-06-17 Initiated Coverage Oppenheimer Outperform $65.00
2015-06-08 Reiterated Rating Piper Jaffray Overweight $59.00
2015-05-09 Reiterated Rating Raymond James Outperform $64.00 to $60.00
2015-05-09 Reiterated Rating Piper Jaffray Overweight $68.00 to $59.00
2015-03-18 Initiated Coverage Robert W. Baird Neutral $55.00
2015-02-12 Boost Price Target Stifel Nicolaus Buy $56.00 to $65.00
2015-02-03 Boost Price Target Barclays Overweight $60.00 to $65.00
2015-01-22 Lower Price Target FBR & Co. Market Perform $54.00 to $50.00
2015-01-08 Boost Price Target FBR & Co. Market Perform $50.00 to $54.00
2014-12-11 Upgrade Stifel Hold to Buy $47
2014-12-11 Boost Price Target Bank of America $65.00
2014-12-11 Upgrade Stifel Nicolaus Hold to Buy $47.00
2014-12-11 Boost Price Target Bank of America Corp. $65.00
2014-11-28 Reiterated Rating Bank of America Positive
2014-11-07 Downgrade Stifel Nicolaus Buy to Hold $65.00
2014-11-07 Reiterated Rating Barclays Overweight $62.00 to $60.00
2014-11-07 Reiterated Rating Bank of America Buy $73.00 to $63.00
2014-09-12 Upgrade Wells Fargo & Co. Market Perform to Outperform
2014-09-12 Upgrade Wells Fargo Market Perform to Outperform
2014-08-14 Initiated Coverage FBR & Co. Market Perform $50.00
2014-08-01 Reiterated Rating Raymond James Outperform $57.00 to $55.00
2014-05-09 Reiterated Rating Raymond James Outperform $68.00 to $57.00
2014-04-15 Reiterated Rating Raymond James Market Perform to Outperform $68.00
2014-04-09 Initiated Coverage SunTrust Buy $78.00
2014-03-05 Initiated Coverage Barclays Overweight $73.00
2014-02-24 Upgrade Ned Davis Research Sell to Neutral
2013-11-06 Downgrade Raymond James Outperform to Market Perform $66.00
2013-11-05 Reiterated Stifel Buy $68 to $75
2013-11-05 Boost Price Target Stifel Nicolaus Buy $68.00 to $75.00
2013-10-14 Initiated Coverage Craig Hallum Buy
2013-10-02 Initiated Coverage Stephens Overweight
2013-09-30 Initiated Coverage KeyBanc Buy $72.00
2013-05-10 Upgrade Northland Capital Market Perform to Outperform $50 to $56
2012-05-08 Initiated Northland Securities Market Perform $100
2011-11-03 Upgrade Stifel Nicolaus Hold to Buy $80
2011-07-01 Downgrade Deutsche Bank Buy to Hold $57 to $57
2011-02-04 Reiterated Deutsche Bank Buy $55 to $57
2010-11-05 Reiterated Deutsche Bank Buy $50 to $55
2010-05-06 Upgrade Deutsche Bank Hold to Buy $35 to $46
2010-01-04 Upgrade William Blair Mkt Perform to Outperform
2009-11-25 Upgrade First Analysis Sec Equal-Weight to Overweight $30
2009-11-24 Initiated Piper Jaffray Overweight $31
2009-02-10 Reiterated Deutsche Securities Hold $24 to $20
2008-10-03 Initiated Stifel Nicolaus Hold
2008-08-06 Reiterated Deutsche Securities Buy $52 to $40
2008-08-06 Downgrade Oppenheimer Outperform to Perform
2008-05-09 Reiterated Deutsche Securities Buy $65 to $52
2007-11-05 Reiterated Friedman Billings Outperform $60 to $70
2007-10-23 Reiterated CIBC Wrld Mkts Sector Outperform $63 to $70
2007-06-15 Initiated CIBC Wrld Mkts Sector Outperform $63
2016-06-20 Initiated Coverage Credit Suisse Outperform $40.00
2016-06-20 Initiated Coverage Credit Suisse Group AG Outperform $40.00
2016-05-29 Reiterated Rating Canaccord Genuity Buy
2016-05-22 Reiterated Rating KeyBanc Hold
2016-05-22 Reiterated Rating KeyCorp Hold

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Musslewhite Robert W Chief Executive Officer 0.73%  (264965) ABCO /
BANSAL SANJU K 0.19%  (70487) ABCO / CSRA / CVT / MSTR /
FELSENTHAL DAVID L President 0.16%  (57703) ABCO /
Kirshbaum Michael T Chief Financial Officer 0.11%  (41171) ABCO /
VAN HOOSE MARY Chief Talent Officer 0.11%  (39084) ABCO /
KINDICK KELT 0.09%  (31808) ABCO / WPX /
Neaman Mark R 0.07%  (25316) ABCO /
Miller Cormac F Executive Vice President 0.06%  (21503) ABCO /
SHAPIRO LEON 0.05%  (19216) ABCO /
SCHWARTZ RICHARD A Executive Vice President 0.05%  (18958) ABCO /
WILLIAMS FRANK J 0.04%  (14701) ABCO /
Killefer Nancy 0.04%  (12856) ABCO / AVP / CAH / CSC / CSRA /
ZUMWALT LEANNE M 0.01%  (4423) ABCO / DVA /
Farber Evan R General Counsel 0.01%  (2610) ABCO /
GRUA PETER J 0.01%  (2423) ABCO / HCN /

Comments